BioLineRx (BLRX) Amortization of Deferred Charges (2019 - 2025)
BioLineRx (BLRX) posted quarterly Amortization of Deferred Charges of $702000.0 for Q1 2025, up 2500.0% quarter-over-quarter from $27000.0 in Q4 2024.
Powered by 
Analysis
BioLineRx (BLRX) Amortization of Deferred Charges (2019 - 2025) Analysis & Trends
BioLineRx's Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $702000.0 for Q1 2025.
- In Q1 2025, Amortization of Deferred Charges changed N/A year-over-year to $702000.0; the TTM figure through Dec 2025 stood at $702000.0 (up 202.59% YoY), while the FY2025 annual figure was $702000.0, up 4.93% from the prior year.
- Amortization of Deferred Charges for Q1 2025 stood at $702000.0, up from $27000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $702000.0 in Q1 2025, with the low at $27000.0 in Q4 2024.
- The 5-year median for Amortization of Deferred Charges is $139000.0 (2022), against an average of $215400.0.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | BioLineRx | 6.46 Bn | 6.46 Bn | 235,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 702,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Mar 31, 2019 | 417,000.00 |